The EMBO Journal · 2010 · 386 citations · 34 references
Life SciencesCell BiologyMolecular BiologyCell CycleChromatin BiologyChromatin StructureCell Cycle ControlCell-cycle RegulationChromatinDna DamageDna Damage SignalingS PhaseChromatin Remodeling After Dna DamageChromatin Remodeling In Dna Damage ResponseChromatin StabilityDamage-induced Chromatin RemodelingDna Damage Checkpoint ActivationDna Damage Checkpoint SignalingDna Damage Responses
The chromatin remodelling factor chromodomain helicase DNA‐binding protein 4 (CHD4) is a catalytic subunit of the NuRD transcriptional repressor complex. Here, we reveal novel functions for CHD4 in the DNA‐damage response (DDR) and cell‐cycle control. We show that CHD4 mediates rapid poly(ADP‐ribose)‐dependent recruitment of the NuRD complex to DNA‐damage sites, and we identify CHD4 as a phosphorylation target for the apical DDR kinase ataxia‐telangiectasia mutated. Functionally, we show that CHD4 promotes repair of DNA double‐strand breaks and cell survival after DNA damage. In addition, we show that CHD4 acts as an important regulator of the G1/S cell‐cycle transition by controlling p53 deacetylation. These results provide new insights into how the chromatin remodelling complex NuRD contributes to maintaining genome stability. This paper adds to the emerging concept that chromatin remodelling contributes to DNA‐damage responses. CHD4, a known NuRD component, is identified as ATM target, localizes to DNA breaks and contributes to repair while associating with PARPylated factors.
34
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139
Emmy P. Rogakou, Duane R. Pilch, Ann H. Orr et al. · Journal of Biological Chemistry · 1998 · 5.4K citations · Full text
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
Catherine Hill, Yuqing Zhang, Bárður Sigurgeirsson et al. · The Lancet · 2001 · 1.2K citations
Medicine, Dermatology, Oncology +14